These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 21342358)

  • 1. Intravenous immune globulin plus corticosteroids in refractory Kawasaki disease.
    Jibiki T; Kato I; Shiohama T; Abe K; Anzai S; Takeda N; Yamaguchi KI; Kanazawa M; Kurosaki T
    Pediatr Int; 2011 Oct; 53(5):729-735. PubMed ID: 21342358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome.
    Inoue Y; Okada Y; Shinohara M; Kobayashi T; Kobayashi T; Tomomasa T; Takeuchi K; Morikawa A
    J Pediatr; 2006 Sep; 149(3):336-341. PubMed ID: 16939743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
    Miyata K; Kaneko T; Morikawa Y; Sakakibara H; Matsushima T; Misawa M; Takahashi T; Nakazawa M; Tamame T; Tsuchihashi T; Yamashita Y; Obonai T; Chiga M; Hori N; Komiyama O; Yamagishi H; Miura M;
    Lancet Child Adolesc Health; 2018 Dec; 2(12):855-862. PubMed ID: 30337183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted use of prednisolone with the second IVIG dose for refractory Kawasaki disease.
    Kimura M; Harazaki M; Fukuoka T; Asakura I; Sakai H; Kamimaki T; Ohkawara I; Akiyama N; Tsurui S; Iwashima S; Shimomura M; Morishita H; Meguro T; Seto S
    Pediatr Int; 2017 Apr; 59(4):397-403. PubMed ID: 27743415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of intravenous immunoglobulin combined with prednisolone following resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease.
    Kobayashi T; Kobayashi T; Morikawa A; Ikeda K; Seki M; Shimoyama S; Ishii Y; Suzuki T; Nakajima K; Sakamoto N; Arakawa H
    J Pediatr; 2013 Aug; 163(2):521-6. PubMed ID: 23485027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corticosteroid pulse combination therapy for refractory Kawasaki disease: a randomized trial.
    Ogata S; Ogihara Y; Honda T; Kon S; Akiyama K; Ishii M
    Pediatrics; 2012 Jan; 129(1):e17-23. PubMed ID: 22144699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of glucocorticoids in Kawasaki disease.
    Miura M
    Int J Rheum Dis; 2018 Jan; 21(1):70-75. PubMed ID: 29105310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Importance of C-reactive protein level in predicting non-response to additional intravenous immunoglobulin treatment in children with Kawasaki disease: a retrospective study.
    Iwashima S; Kimura M; Ishikawa T; Ohzeki T
    Clin Drug Investig; 2011; 31(3):191-9. PubMed ID: 21456105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of intravenous immune globulin therapy combined with dexamethasone for the initial treatment of acute Kawasaki disease.
    Jibiki T; Terai M; Kurosaki T; Nakajima H; Suzuki K; Inomata H; Terashima I; Honda T; Yasukawa K; Hamada H; Kohno Y
    Eur J Pediatr; 2004 Apr; 163(4-5):229-33. PubMed ID: 14963702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylprednisolone pulse and prednisolone for intensification of primary treatment in Kawasaki disease patients at high risk of treatment resistance: a multicenter prospective cohort study.
    Miura M; Miyata K; Kaneko T; Akahoshi S; Morikawa Y; Matsushima T; Sakakibara H; Kobayashi T; Nakamura T; Takahashi T; Nakazawa M; Shibata A; Yamagishi H
    Eur J Pediatr; 2024 Oct; 183(10):4265-4274. PubMed ID: 39048743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coronary artery lesions and the increasing incidence of Kawasaki disease resistant to initial immunoglobulin.
    Kibata T; Suzuki Y; Hasegawa S; Matsushige T; Kusuda T; Hoshide M; Takahashi K; Okada S; Wakiguchi H; Moriwake T; Uchida M; Ohbuchi N; Iwai T; Hasegawa M; Ichihara K; Yashiro M; Makino N; Nakamura Y; Ohga S
    Int J Cardiol; 2016 Jul; 214():209-15. PubMed ID: 27070994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of three intravenous gamma globulin regimens on Kawasaki disease and relevant coronary complication rates in pediatric patients: a comparative study].
    DU ZD; Zhao D; DU JB; Lu S; Yi JM; Hou AC; Zhou ZS; Ding GF;
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(44):3119-21. PubMed ID: 18269869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease.
    Kuo HC; Lo MH; Hsieh KS; Guo MM; Huang YH
    PLoS One; 2015; 10(12):e0144603. PubMed ID: 26658843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Use of Prednisolone with Intravenous Immunoglobulin for Kawasaki Disease.
    Sakai H; Iwashima S; Sano S; Akiyama N; Nagata E; Harazaki M; Fukuoka T
    Clin Drug Investig; 2021 Jan; 41(1):77-88. PubMed ID: 33341911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Multicenter Study of Intravenous Immunoglobulin Non-response in Kawasaki Disease.
    Wei M; Huang M; Chen S; Huang G; Huang M; Qiu D; Guo Z; Jiang J; Zhou X; Yu Q; Guo Y; Fu L; Gao W; Li F
    Pediatr Cardiol; 2015 Aug; 36(6):1166-72. PubMed ID: 25812827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum tenascin-C predicts resistance to steroid combination therapy in high-risk Kawasaki disease: a multicenter prospective cohort study.
    Yoshikane Y; Okuma Y; Miyamoto T; Hashimoto J; Fukazawa R; Kato T; Takeda A; Suda K; Matsushita T; Hiroe M; Imanaka-Yoshida K
    Pediatr Rheumatol Online J; 2021 Jun; 19(1):82. PubMed ID: 34090475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes of initial dexamethasone treatment combined with a single high dose of intravenous immunoglobulin for primary treatment of Kawasaki disease.
    Lim YJ; Jung JW
    Yonsei Med J; 2014 Sep; 55(5):1260-6. PubMed ID: 25048483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fever pattern and C-reactive protein predict response to rescue therapy in Kawasaki disease.
    Nakagama Y; Inuzuka R; Hayashi T; Shindo T; Hirata Y; Shimizu N; Inatomi J; Yokoyama Y; Namai Y; Oda Y; Takamizawa M; Harita Y; Oka A
    Pediatr Int; 2016 Mar; 58(3):180-184. PubMed ID: 26222760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk stratification in the decision to include prednisolone with intravenous immunoglobulin in primary therapy of Kawasaki disease.
    Kobayashi T; Inoue Y; Otani T; Morikawa A; Kobayashi T; Takeuchi K; Saji T; Sonobe T; Ogawa S; Miura M; Arakawa H
    Pediatr Infect Dis J; 2009 Jun; 28(6):498-502. PubMed ID: 19504733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum Tenascin-C as a Novel Predictor for Risk of Coronary Artery Lesion and Resistance to Intravenous Immunoglobulin in Kawasaki Disease　- A Multicenter Retrospective Study.
    Okuma Y; Suda K; Nakaoka H; Katsube Y; Mitani Y; Yoshikane Y; Ichida F; Matsushita T; Shichino H; Shiraishi I; Abe J; Hiroe M; Yoshida T; Imanaka-Yoshida K
    Circ J; 2016 Oct; 80(11):2376-2381. PubMed ID: 27746411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.